Founded in 2007, Mach7 Technologies excels as a market leader born of innovation and growing through strategic partnerships. Our team of industry experts brings hundreds of years of experience to customer partnerships where our culture of collaboration fosters innovation through new and improved patient-focused solutions. Mach7 brings a fresh approach to enterprise imaging management and workflow that pulls from the latest technologies and the brightest minds to deliver cutting edge solutions. The company provides award-winning vendor neutral archive technology to improve enterprise imaging data storage, sharing and interoperability across healthcare enterprises. Patent-awarded mobile technology extends this advanced enterprise imaging solution technology to mobile devices, further differentiating Mach7 as a healthcare technology leader.
Mach7 Technologies’ solutions are leveraged by global healthcare enterprises to unlock patient data, unleash care intelligence and fundamentally shift the management, sharing and use of medical imaging to power the healthcare enterprise ecosystem. Mach7 solutions allow patient data and patient care intelligence to be used in more meaningful ways to achieve systemic efficiencies, improve practitioner effectiveness and offer improved outcomes for patient.
Head of Investor Relations
Mach7 Technologies Limited
+61 (0) 416 079 329
Sydney NSW, 2000
+61 (0) 401 809 653
Level 6, 350 Collins Street
Melbourne, Vic, 3000
Mach7 Technologies (ASX:M7T) at the Bell Potter Healthcare Conference 2022
Mike Lampron, Mach7’s Chief Executive Officer & Managing Director, recently presented at the 2022 Bell Potter Healthcare Conference. In this video, Mike provides a business overview of Mach7, including discussing our business, market, products, customers, global footprint, partners, value proposition, differentiators, revenue model, and our FY21 results. You can click this link to watch the original video on YouTube.
Biotech Daily Article – Dr. Boreham’s Crucible: Mach7 Technologies
Mach7 has been featured in the November 11, 2022 edition of Biotech Daily’s “Dr. Boreham’s Crucible.” This is a great summary about the company, highlighting some of its current financials, and how it stacks up against some of its closest competitors. You can read and download the article here, or visit Biotech Daily’s website for more.
Mach7 Technologies – Annual Report for FY22
FY22 Results Investor Webinar
The company has released its 2022 fiscal year (FY22) results, in which it reported record-setting financial results. Highlights include record revenues of $27.1M (up $8.1M or 42% yoy), annual recurring revenue (ARR) run rate $14.4M (up 7.5%), record positive operating cashflows of $6.3M (up $4.8M or 320% yoy), recrod gross margin of $26.1M or 96% (up $7.7M or 42% yoy), and EBITDA of $2.8M (up $4.6M or 253% yoy). You can read FY22 Results Announcement here. Additionally, Mach7 has also released its Preliminary Final report and Audited Full Year Accounts, available here.
In this recorded live stream, Mike Lampron (CEO, Mach7) and Steve Parkes (Global CFO, Mach7) walk through the FY22 results and answer questions from the audience. You can view the presentation used in the livestream at this link, and access the livestream itself with this link.
Mach7 Technologies – Annual Report for FY21
Bulls N’ Bears – Mach7 Technologies CEO Interview
Mike Lampron, CEO of Mach7, was recently interviewed by Matt Birney on his podcast Bulls N’ Bears to discuss the Company’s FY21 results.
FY21 Results Investor Presentation
Mach7 has announced its 2021 fiscal year (FY21) results, in which it reported $25.6M in sales orders (total contract value), its highest on record. You can read FY21 Results Announcement here. Additionally, Mach7 has also released its Preliminary Final report and Audited Full Year Accounts, available here.
In this recorded live stream, Mike Lampron (CEO, Mach7), Jenni Pilcher (CFO, Mach7), and Andrew Keys (Investor Relations, Keys Thomas Associates) walk through the FY21 results and answer questions from the audience. You can view the presentation used in the livestream at this link.
Fourth Quarter FY21 Results
The company recently announced its Fourth Quarter FY21 Results, in which it reported 95% sales order growth for FY21, as well as a number of customer expansions and renewals. You can read the ASX Release here.
In this recorded live stream, Mike Lampron (CEO, Mach7), Jenni Pilcher (CFO, Mach7), and Andrew Keys (Investor Relations, Keys Thomas Associates) discuss the results and answer questions about the business and the healthcare IT market landscape.
Third Quarter FY21 Results
In Mach7’s Third Quarter FY2021 Results, it reported record quarterly cash receipts, leading to strong operating cash flows. You can read the official announcement here.
You can click the thumbnail to watch the video interview.